Biohaven Pharmaceuticals
6 known investors
Find your way into Biohaven Pharmaceuticals
62 people in our graph share verified history with the Biohaven Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.
Karthik Ardhanareeswaranunlockedknows Vlad Coric · together at Yale School of Medicine (overlapped)
×11knows the team · via Yale School of Medicine
Biohaven is a biopharmaceutical company that discovers, develops, and commercializes treatments across immunology, obesity, neuroscience, and oncology, targeting rare and common diseases with limited treatment options. Its commercialized products include migraine therapies, and it advances a portfolio of early- to late-stage drug development programs.
Founders & leadership
VC
Vlad CoricinChairman & Chief Executive OfficerVlad Coric is Chairman and Chief Executive Officer of Biohaven Pharmaceuticals, a biopharmaceutical company developing treatments in neuroscience, immunology, metabolic disorders, rare disease, and oncology. He has over 25 years of clinical and research experience and previously led development of Nurtec ODT, a migraine treatment that was acquired by Pfizer.
Investors · 6
In the news
Frequently asked questions
- What does Biohaven Pharmaceuticals do?
- Biohaven is a biopharmaceutical company that discovers, develops, and commercializes treatments across immunology, obesity, neuroscience, and oncology, targeting rare and common diseases with limited treatment options. Its commercialized products include migraine therapies, and it advances a portfolio of early- to late-stage drug development programs.
- Who are Biohaven Pharmaceuticals's investors?
- Biohaven Pharmaceuticals's investors include Aisling Capital, APERTURE Venture Partners, Connecticut Innovations, OUP (Osage University Partners), HBM Healthcare Investments, OrbiMed.